Perez-Garcia, Jose Manuel
Cortes, Javier http://orcid.org/0000-0001-7623-1583
Llombart-Cussac, Antonio
Article History
First Online: 8 November 2021
Competing interests
: J.P.-G. reports consulting or advisory service for Roche, Daichii Sankyo, AstraZeneca, Lilly and Seattle Genetics; and travel, accommodation and expenses from Roche. J.C. reports consulting or advisory service for Roche, Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp & Dohme, GlaxoSmithKline, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab and Gilead; honoraria from AstraZeneca, Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp & Dohme and Daiichi Sankyo; research funding to the International Breast Cancer Center from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman-La Roche, Guardanth Health, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Puma C and Queen Mary University of London; stock, patents and intellectual property with MedSIR; and travel, accommodation and expenses from Roche, Novartis, Eisai, Pfizer and Daiichi Sankyo. Antonio Llombart-Cussac reports consulting or advisory service for AstraZeneca, Celgene, Novartis, Pfizer, Roche, Eli Lilly and TESARO; expert testimony for AstraZeneca and Sanofi; research funding from Eisai, Roche, Pfizer, Eli Lilly, Merck Sharp & Dohme, Eli Lilly and Pierre Fabre; stock, patents and intellectual property with MedSIR; and travel, accommodation and expenses from Roche, Celgene, Pfizer, GE Healthcare and Eli Lilly.